Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2017 - 2025)

Dr Reddys Laboratories (RDY) has 7 years of Liabilities and Shareholders Equity data on record, last reported at $125.8 million in Q1 2023.

  • For Q1 2023, Liabilities and Shareholders Equity fell 5.66% year-over-year to $125.8 million; the TTM value through Mar 2024 reached $391.8 million, down 21.24%, while the annual FY2023 figure was $128.9 million, 4.24% down from the prior year.
  • Liabilities and Shareholders Equity reached $125.8 million in Q1 2023 per RDY's latest filing, down from $133.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $133.4 million in Q1 2022 and bottomed at $93.1 million in Q1 2019.
  • Average Liabilities and Shareholders Equity over 5 years is $118.1 million, with a median of $125.8 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 25.48% in 2021, then dropped 5.66% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $93.1 million in 2019, then increased by 13.5% to $105.7 million in 2020, then grew by 25.48% to $132.6 million in 2021, then grew by 0.57% to $133.4 million in 2022, then decreased by 5.66% to $125.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $125.8 million in Q1 2023, $133.4 million in Q1 2022, and $132.6 million in Q1 2021.